NCT07402876
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
At risk: Primary completion moved at least 2 years 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Dec 2026 to Dec 2029
- Start date: Feb 2026 to Dec 2027
- Eligibility criteria expanded, about 9 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment
Timeframe: Eight weeks
Arms and interventions
Induction/Consolidation/Maintenance (ICM) ADX-2191 injectionExperimental
Monthly ADX-2191 injectionActive comparator
Drugs: ICM ADX-2191 injection, Monthly ADX-2191 injection
Sites
1 site in 1 country
- Bascom Palmer Eye InstituteMiami, Florida, United States